A Paradigm Shift in Oncology and its Treatment: A Review Cancer research
Main Article Content
Article Sidebar
Published
Sep 18, 2021
Manjunatha Reddy
Dr
Prutha Vijaykumar
Abstract
The present standard therapies for cancer; surgery, anti-cancer drugs and radiotherapy, have major issues in advanced cancers especially, it is unlikely that they will cure the disease permanently. They require huge medical expenditure and the adverse side effects accompanying them put many patients in anguish. These problems may be considered as a result of initiating treatments without considering the root cause of cancer- "the change in energy metabolism". Tumor cells have unique metabolic characteristics, and henceforth cancer can be treated as a metabolic disease and be interfered at different stages of cell metabolism. Cancer, also being characterized by an immunological imbalance, focusing on targeting, involving and regulating cancer-associated immune cells in the tumor microenvironment (TME) with nanomedicines can potentially become a great tool to stop cancer. Stem cells and mAbs have the capability to come handy in targeting the immune system, which demands more clinical research to be done.
How to Cite
Reddy, M., Manokaran, S., & Vijaykumar, P. (2021). A Paradigm Shift in Oncology and its Treatment: A Review : Cancer research. SPAST Abstracts, 1(01). Retrieved from https://spast.org/techrep/article/view/699
Article Details
Keywords
Oncology, Cancer, radiotherapy, tumor, mAbs
References
1. Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal and Freddie Bray, Global cancer statistics 2020, ACS Journals, 04 Feb 2021.
2. O. Warburg, On the origin of cancer cells, Science, 24 Feb 1956.
3. Douglas Hanahan and Robert A Weinberg, Hallmarks of cancer: the next generation, Cell, 2011.
4. Thomas N Seyfried and Laura M Shelton, Cancer as a metabolic disease, Nutrition & Metabolism, 27 Jan 2010.
5. Buddhini Samarasinghe, The Hallmarks of Cancer 9: Reprogramming energy metabolism, Scientific American, 8 Oct 2014.
6. Dario Neri and Claudiu T Supuran, Interfering with pH regulation in tumours as a therapeutic strategy, Nat Rev Drug Discov., 16 Sept 2011.
7. A Carracedo and P P Pandolfi, The PTEN–PI3K pathway: of feedbacks and cross-talks, Oncogene, 15 Sept 2008.
8. Yi Zhang and Jin-Ming Yang, Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention, Cancer biology & therapy, Feb 2013.
9. Javier A Menendez and Ruth Lupu, Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis, Nat Rev Cancer, Oct 2007.
10. Lisa M Coussens and Zena Werb, Inflammation and cancer, Nature, Dec 2002.
11. Sergei I Grivennikov, Florian R Greten and Michael Karin, Immunity, inflammation, and cancer, Cell, 1 Mar 2010.
12. Yifeng Xia, Shen Shen and Inder M Verma, NF-κB, an active player in human cancers, Cancer immunology research , Sept 2014.
13. Raghu Kalluri and Robert A Weinberg, The basics of epithelial-mesenchymal transition, J Clin Invest. Jun 2009.
14. Yu M, Bardia A, Wittner B S, Shannon L. Stott, Malgorzata E. Smas, David T. Ting, Steven J. Isakoff, Jordan C. Ciciliano, Marissa N. Wells, Ajay M. Shah, Kyle F. Concannon, Maria C. Donaldson, Lecia V. Sequist, Elena Brachtel, Dennis Sgroi, Jose Baselga, Sridhar Ramaswamy, Mehmet Toner, Daniel Haber And Shyamala Maheswaran, Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition, Science, Feb 2013.
15. Ricciardi, M., Zanotto, M., Malpeli, G Bassi, O Perbellini, M Chilosi, F Bifari & M Krampera, Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells, Br J Cancer, Mar 2015.
16. Peer, Dan, Jeffrey M. Karp, Seungpyo Hong, Omid C. Farokhzad, Rimona Margalit, and Robert Langer, Nanocarriers as an emerging platform for cancer therapy, Nature, Dec 2007.
17. Wilhelm, Stefan, Anthony J. Tavares, Qin Dai, Seiichi Ohta, Julie Audet, Harold F. Dvorak, and Warren CW Chan, Analysis of nanoparticle delivery to tumors, Nature Reviews, Apr 2016.
18. Wildes, Tyler J., Catherine T. Flores, and Duane A. Mitchell, Concise review: modulating cancer immunity with hematopoietic stem and progenitor cells, Stem Cells, Feb 2019.
19. Hans Clevers, The cancer stem cell: premises, promises and challenges, Nat. Med., Mar 2011.
20. Mel Greaves and Carlo C. Maley, Clonal evolution in cancer, Nature, Jan 2012.
21. Yang Shi and Twan Lammers, Combining Nanomedicine and Immunotherapy, Accounts of chemical research, Jun 2019.
22. Mathios D, Kim JE, Mangraviti A, Phallen J, Park CK, Jackson CM, Garzon-Muvdi T, Kim E, Theodros D, Polanczyk M and Martin AM, Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM, Sci Transl Med., Dec 2016.
23. Lukas W. Pfannenstiel, Samuel S. K. Lam, Leisha A. Emens, Elizabeth M. Jaffee and Todd D. Armstrong, Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice, Cell Immunol., 2010.
24. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC and Vonderheide RH, Understanding the tumor immune microenvironment (TIME) for effective therapy, Nat Med., May 2018.
25. Kim HY, Li R, Ng TS, Courties G, Rodell CB, Prytyskach M, Kohler RH, Pittet MJ, Nahrendorf M, Weissleder R and Miller MA, Quantitative Imaging of Tumor-Associated Macrophages and Their Response to Therapy Using 64Cu-Labeled Macrin, ACS nano, Dec 2018.
26. Sun Q, Barz M, De Geest BG, Diken M, Hennink WE, Kiessling F, Lammers T, Shi Y, Nanomedicine and macroscale materials in immuno-oncology, Chem Society Rev., 2019.
27. Irvine, D.J., Dane, E.L. Enhancing cancer immunotherapy with nanomedicine, Nature Rev. Immunology, Jan 2020.
28. R A Miller, D G Maloney, R Warnke and R Levy, Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody, N. Engl. J. Med., Mar 1982.
29. Joshua Brody, Holbrook Kohrt, Aurelien Marabelle and Ronald Levy, Active and passive immunotherapy for lymphoma: proving principles and improving results, J. Clin. Oncol., May 2011.
30. Jacques Descotes, Immunotoxicity of monoclonal antibodies, mAbs, Mar-Apr 2009.
31. Chu DT, Nguyen TT, Tien NL, Tran DK, Jeong JH, Anh PG, Thanh VV, Truong DT, Dinh TC, Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications, Cells, 2020.
2. O. Warburg, On the origin of cancer cells, Science, 24 Feb 1956.
3. Douglas Hanahan and Robert A Weinberg, Hallmarks of cancer: the next generation, Cell, 2011.
4. Thomas N Seyfried and Laura M Shelton, Cancer as a metabolic disease, Nutrition & Metabolism, 27 Jan 2010.
5. Buddhini Samarasinghe, The Hallmarks of Cancer 9: Reprogramming energy metabolism, Scientific American, 8 Oct 2014.
6. Dario Neri and Claudiu T Supuran, Interfering with pH regulation in tumours as a therapeutic strategy, Nat Rev Drug Discov., 16 Sept 2011.
7. A Carracedo and P P Pandolfi, The PTEN–PI3K pathway: of feedbacks and cross-talks, Oncogene, 15 Sept 2008.
8. Yi Zhang and Jin-Ming Yang, Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention, Cancer biology & therapy, Feb 2013.
9. Javier A Menendez and Ruth Lupu, Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis, Nat Rev Cancer, Oct 2007.
10. Lisa M Coussens and Zena Werb, Inflammation and cancer, Nature, Dec 2002.
11. Sergei I Grivennikov, Florian R Greten and Michael Karin, Immunity, inflammation, and cancer, Cell, 1 Mar 2010.
12. Yifeng Xia, Shen Shen and Inder M Verma, NF-κB, an active player in human cancers, Cancer immunology research , Sept 2014.
13. Raghu Kalluri and Robert A Weinberg, The basics of epithelial-mesenchymal transition, J Clin Invest. Jun 2009.
14. Yu M, Bardia A, Wittner B S, Shannon L. Stott, Malgorzata E. Smas, David T. Ting, Steven J. Isakoff, Jordan C. Ciciliano, Marissa N. Wells, Ajay M. Shah, Kyle F. Concannon, Maria C. Donaldson, Lecia V. Sequist, Elena Brachtel, Dennis Sgroi, Jose Baselga, Sridhar Ramaswamy, Mehmet Toner, Daniel Haber And Shyamala Maheswaran, Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition, Science, Feb 2013.
15. Ricciardi, M., Zanotto, M., Malpeli, G Bassi, O Perbellini, M Chilosi, F Bifari & M Krampera, Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells, Br J Cancer, Mar 2015.
16. Peer, Dan, Jeffrey M. Karp, Seungpyo Hong, Omid C. Farokhzad, Rimona Margalit, and Robert Langer, Nanocarriers as an emerging platform for cancer therapy, Nature, Dec 2007.
17. Wilhelm, Stefan, Anthony J. Tavares, Qin Dai, Seiichi Ohta, Julie Audet, Harold F. Dvorak, and Warren CW Chan, Analysis of nanoparticle delivery to tumors, Nature Reviews, Apr 2016.
18. Wildes, Tyler J., Catherine T. Flores, and Duane A. Mitchell, Concise review: modulating cancer immunity with hematopoietic stem and progenitor cells, Stem Cells, Feb 2019.
19. Hans Clevers, The cancer stem cell: premises, promises and challenges, Nat. Med., Mar 2011.
20. Mel Greaves and Carlo C. Maley, Clonal evolution in cancer, Nature, Jan 2012.
21. Yang Shi and Twan Lammers, Combining Nanomedicine and Immunotherapy, Accounts of chemical research, Jun 2019.
22. Mathios D, Kim JE, Mangraviti A, Phallen J, Park CK, Jackson CM, Garzon-Muvdi T, Kim E, Theodros D, Polanczyk M and Martin AM, Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM, Sci Transl Med., Dec 2016.
23. Lukas W. Pfannenstiel, Samuel S. K. Lam, Leisha A. Emens, Elizabeth M. Jaffee and Todd D. Armstrong, Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice, Cell Immunol., 2010.
24. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC and Vonderheide RH, Understanding the tumor immune microenvironment (TIME) for effective therapy, Nat Med., May 2018.
25. Kim HY, Li R, Ng TS, Courties G, Rodell CB, Prytyskach M, Kohler RH, Pittet MJ, Nahrendorf M, Weissleder R and Miller MA, Quantitative Imaging of Tumor-Associated Macrophages and Their Response to Therapy Using 64Cu-Labeled Macrin, ACS nano, Dec 2018.
26. Sun Q, Barz M, De Geest BG, Diken M, Hennink WE, Kiessling F, Lammers T, Shi Y, Nanomedicine and macroscale materials in immuno-oncology, Chem Society Rev., 2019.
27. Irvine, D.J., Dane, E.L. Enhancing cancer immunotherapy with nanomedicine, Nature Rev. Immunology, Jan 2020.
28. R A Miller, D G Maloney, R Warnke and R Levy, Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody, N. Engl. J. Med., Mar 1982.
29. Joshua Brody, Holbrook Kohrt, Aurelien Marabelle and Ronald Levy, Active and passive immunotherapy for lymphoma: proving principles and improving results, J. Clin. Oncol., May 2011.
30. Jacques Descotes, Immunotoxicity of monoclonal antibodies, mAbs, Mar-Apr 2009.
31. Chu DT, Nguyen TT, Tien NL, Tran DK, Jeong JH, Anh PG, Thanh VV, Truong DT, Dinh TC, Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications, Cells, 2020.
Section
NB:Biology